Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease
- PMID: 22231990
- DOI: 10.1002/ajmg.b.32016
Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease
Abstract
We aimed to address gaps in current understanding of the scope and impact of discrimination, by examining a cohort of individuals at-risk for Huntington disease (HD), to describe the prevalence of concern for oneself and one's family in multiple domains; strategies used to mitigate discrimination; and the extent to which concerns relate to experiences. We conducted a cross-sectional survey of 293 individuals at-risk for HD (80% response rate); 167 respondents were genetically tested and 66 were not. Fear of discrimination was widespread (86%), particularly in the insurance, family and social settings. Approximately half of concerned individuals experienced discrimination (40-62%, depending on genetic status). Concern was associated with "keeping quiet" about one's risk of HD or "taking action to avoid" discrimination. Importantly, concern was highly distressing for some respondents (21% for oneself; 32% for relatives). Overall, concerned respondents with high education levels, who discovered their family history at a younger age, and those who were mutation-positive were more likely to report experiences of discrimination than others who were concerned. Concerns were rarely attributed to genetic test results alone. Concern about genetic discrimination is frequent among individuals at-risk of HD and spans many settings. It influences behavioral patterns and can result in high levels of self-rated distress, highlighting the need for practice and policy interventions. © 2012 Wiley Periodicals, Inc.
Copyright © 2012 Wiley Periodicals, Inc.
Similar articles
-
Factors associated with experiences of genetic discrimination among individuals at risk for Huntington disease.Am J Med Genet B Neuropsychiatr Genet. 2011 Jan;156B(1):19-27. doi: 10.1002/ajmg.b.31130. Epub 2010 Nov 10. Am J Med Genet B Neuropsychiatr Genet. 2011. PMID: 21184581 Free PMC article.
-
Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey.BMJ. 2009 Jun 9;338:b2175. doi: 10.1136/bmj.b2175. BMJ. 2009. PMID: 19509425 Free PMC article.
-
Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease.Eur J Hum Genet. 2008 Mar;16(3):279-89. doi: 10.1038/sj.ejhg.5201937. Epub 2007 Oct 24. Eur J Hum Genet. 2008. PMID: 17957229 Free PMC article.
-
Genetic counseling and testing for Huntington's disease: A historical review.Am J Med Genet B Neuropsychiatr Genet. 2017 Jan;174(1):75-92. doi: 10.1002/ajmg.b.32453. Epub 2016 May 13. Am J Med Genet B Neuropsychiatr Genet. 2017. PMID: 27174011 Review.
-
Genetic testing and mental health: the model of Huntington disease.Online J Issues Nurs. 2000;5(3):3. Online J Issues Nurs. 2000. PMID: 11380269 Review.
Cited by
-
Genetics and Personal Insurance: the Perspectives of Canadian Cancer Genetic Counselors.J Genet Couns. 2015 Dec;24(6):1022-36. doi: 10.1007/s10897-015-9841-9. Epub 2015 May 1. J Genet Couns. 2015. PMID: 25925606 Free PMC article.
-
Global trends on fears and concerns of genetic discrimination: a systematic literature review.J Hum Genet. 2016 Apr;61(4):275-82. doi: 10.1038/jhg.2015.151. Epub 2016 Jan 7. J Hum Genet. 2016. PMID: 26740237
-
Implications pour les soins de santé de la Loi sur la non-discrimination génétique: La protection des renseignements génétiques des Canadiens.Can Fam Physician. 2022 Sep;68(9):e252-e255. doi: 10.46747/cfp.6809e252. Can Fam Physician. 2022. PMID: 36100382 Free PMC article. French. No abstract available.
-
Benefits and Risks of Sharing Genomic Data for Research: Comparing the Views of Rare Disease Patients, Informal Carers and Healthcare Professionals.Int J Environ Res Public Health. 2022 Jul 19;19(14):8788. doi: 10.3390/ijerph19148788. Int J Environ Res Public Health. 2022. PMID: 35886636 Free PMC article.
-
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.Neurology. 2014 Mar 11;82(10):850-7. doi: 10.1212/WNL.0000000000000187. Epub 2014 Feb 7. Neurology. 2014. PMID: 24510496 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical